106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2017 All rights reserved
ESGEN17123a
Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality
patient care. It focuses on the needs of primary care practice, but also is applicable to providers
at all levels. is Guideline should not be considered exclusive of other methods of care
reasonably directed at obtaining the same results. e ultimate judgment concerning the
propriety of any course of conduct must be made by the clinician aer consideration of each
individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service
associated with the distributor of this clinical reference tool.
Source
Hembree WC et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent
Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab.
November 2017. 102(11):1–35.
Abbreviations
DSM, Diagnostic and Statistical Manual of Mental Disorders; DXA, dual-energ y X-ray
absorptiometry; E2, estradiol; FSH, follicle stimulating hormone; GD, gender dysphoria;
GD/GI, gender dysphoria/gender incongruence; GI, gender incongruence; GnRH,
gonadotropin-releasing hormone; MHP, mental health professional; ICD, International
Statistical Classification of Diseases and Related Health Problems; IM, intramuscularly;
LH, luteinizing hormone; SC, subcutaneously; SQ, sequentially; T, testosterone; UGPS,
Ungraded Good Practice Statement
Grading System
Strength of
Recommendation
1 = strong 2 = weak UGPS = ungraded
good practice statement
Quality of
Evidence
⊕⊕⊕⊕
= high
⊕⊕⊕
= moderate
⊕⊕
= low
⊕
= very low